Glukóza B. Braun

Glukóza B. Braun is a sterile glucose monohydrate solution for injection, supplied in a standard concentration for intravenous use. It is a prescription‑only carbohydrate solution marketed in the European Union. The product provides an exogenous source of glucose to support energy metabolism during parenteral therapy, fluid replacement, and intraoperative care. Formulated as a clear aqueous solution, it is administered by healthcare professionals under controlled clinical conditions.

Glukóza B. Braun is indicated for several clinical situations where rapid provision of glucose and fluid balance is required.

- Treatment of hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens for patients unable to receive enteral feeding. - Fluid and electrolyte replacement in perioperative or critical‑care settings. - Intraoperative energy source to maintain blood glucose during surgery. - Dilution medium for certain intravenous medications requiring a carbohydrate carrier. - Support of metabolic demands in patients with prolonged fasting or catabolic states.

Adverse reactions to Glukóza B. Braun are generally related to its osmolarity, glucose content, and infusion rate.

Common: - Mild hyperglycemia, especially in patients with impaired glucose tolerance. - Local irritation or pain at the infusion site. - Nausea or transient vomiting. - Electrolyte shifts such as mild hyponatremia. - Transient headache or dizziness. - Mild metabolic acidosis in high infusion rates.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hyperosmolar hyperglycemic state (HHS) in susceptible individuals. - Fluid overload causing pulmonary edema. - Allergic reactions ranging from urticaria to anaphylaxis. - Severe electrolyte disturbances such as hyperkalemia. - Rapid rise in serum osmolality with neurologic symptoms.

When prescribing Glukóza B. Braun, clinicians should evaluate patient-specific factors and monitor relevant parameters to minimize risks.

- Assess blood glucose levels before and during infusion, adjusting rate as needed. - Use caution in patients with diabetes mellitus or impaired insulin response. - Monitor fluid balance to avoid overload, especially in heart or renal failure. - Check electrolyte status, particularly sodium and potassium, before administration. - Avoid rapid bolus injections; infuse over a controlled period. - Consider compatibility with other IV solutions; do not mix with calcium‑containing fluids. - Pregnant or lactating patients should be evaluated individually due to limited safety data.

Glukóza B. Braun may interact with other intravenous agents or affect the pharmacodynamics of concurrent medications.

Avoid: - Co‑administration with calcium‑containing solutions, which can precipitate calcium gluconate. - Simultaneous infusion with high‑dose insulin without appropriate glucose monitoring. - Mixing with hypertonic saline solutions, which can increase osmolar load.

Use with caution: - Concurrent use of diuretics that may exacerbate electrolyte shifts. - Beta‑blockers that mask hypoglycemia symptoms. - Corticosteroids that increase glucose production. - Vasopressors that may alter peripheral perfusion and affect infusion site tolerance. - Concurrent total parenteral nutrition formulations, requiring careful monitoring of total carbohydrate load.